Targets › HCRT
3 programs from 3 companies in 10 trials: 7 Phase 2, 3 Phase 3; Neurology; next expected readout Nov 2026.
Neuropeptides that play a significant role in the regulation of food intake and sleep-wakefulness, possibly by coordinating the complex behavioral and physiologic responses of these complementary homeostatic functions. A broader role in the homeostatic regulation of energy metabolism, autonomic function, hormonal balance and the regulation of body fluids, is also suggested..; FUNCTION: [Orexin-A]: Binds to orexin…. (UniProt, O43612)
Open in Phaseline: the race on HCRT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Alkermes | ALKS 2680 Hypocretin/orexin pathway modulator | HCRT | Phase 3 | Narcolepsy Type 1; Narcolepsy Type 2; Idiopathic Hypersomnia | Nov 2026 |
| Takeda | TAK-360 Orexin receptor agonist | HCRT | Phase 2 | Idiopathic Hypersomnia; Narcolepsy Type 2; Narcolepsy Type 1 | Nov 2026 |
| Centessa Pharmaceuticals (UK) | cleminorexton Orexin receptor agonist | HCRT | Phase 2 | Narcolepsy Type 1 | Sep 2027 |
Narcolepsy Type 1 (5) Idiopathic Hypersomnia (3) Narcolepsy Type 2 (2)
small molecule (3)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.